Últimas noticias sobre AdvisorShares Hotel ETF (ARCA:BEDZ)

Consumer Cyclical

Real Estate

Energy

Communication Services

The Fund is an actively managed exchange-traded fund (ETF) that seeks to achieve its investment objective by investing, under normal circumstances, at least 80 percent of its net assets (plus any borrowings for investment purposes) in securities of companies that derive at least 50 percent of their net revenue from the hotel business. The Fund defines companies in the hotel business as those in the hotels, resorts and cruise lines sub-industry, which consists of owners and operators of hotels (generally excluding casino-hotels), resorts, and cruise-ships and includes travel agencies, tour operators and related services not classified elsewhere. The Fund may also invest in companies involved in other lodging and travel-related services.

Priceline.com, Inc.

Expedia Group Inc.

Xenia Hotels & Resorts Inc

Royal Caribbean Cruises Ltd.

Target Hospitality Corp Com

Intercontinental Hotels Group Plc, Adr

Norwegian Cruise Line Holdings Ltd.

Apple Hospitality Reit Inc

Host Hotels & Resorts Inc.

Ryman Hospitality Properties

Viking Holdings Ltd

Carnival Corp.

Atour Lifestyle Holdings Ltd

Travel + Leisure Co

Boyd Gaming Corp

Travelzoo

Pebblebrook Hotel Trust

Diamondrock Hospitality Co

Gaming & Leisure Pptys Inc

Summit Hotel Properties Inc

Tripadvisor Inc.

Rlj Lodging Trust

Vici Properties Inc

Hilton Worldwide Holdings, Inc.

Playa Hotels And Resorts Nv

AdvisorShares Hotel ETF

Earnings

Equities

Large Cap

News

Dividends

Buybacks

Movers

BEDZ

PowerShares Golden Dragon Halter USX China Portfolio

TCOM

Trip.com reportó un BPA superior al esperado y un aumento en ingresos. Sin embargo, sus acciones caen antes de la apertura del mercado.

Acciones de Trip.com (TCOM) caen pese a sólidos resultados trimestrales

Benchmark analyst Bruce Jackson initiates coverage on CapsoVision (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CV#NASDAQ">CV</a>) with a Speculative Buy rating and announces Price Target of $5.

Price Target

Initiation

Analyst Ratings

Benchmark Initiates Coverage On CapsoVision with Speculative Buy Rating, Announces Price Target of $5

No common stock was repurchased in the second quarter of 2025. On July 24, 2025, the Board of Directors authorized a new 5% buyback authorization, for 499,000 shares of the Company's common stock in open market or private transactions. The timing and amount of any share repurchases under the new authorization will be determined by management based on market conditions and other considerations. The new share repurchase authorization does not obligate the Company to repurchase any shares of its common stock.

CZWI

Citizens Community Bancorp Board Of Directors Authorized A New 5% Common Stock Buyback Authorization, Or 499,000 Shares.

Citizens Community (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZWI#NASDAQ">CZWI</a>) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0.29 by 13.79 percent. This is a 8.33 percent decrease over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $16.147 million which beat the analyst consensus estimate of $12.100 million by 33.45 percent. This is a 19.70 percent increase over sales of $13.489 million the same period last year.

Earnings Beats

Citizens Community Q2 Adj. EPS $0.33 Beats $0.29 Estimate, Sales $16.147M Beat $12.100M Estimate

Benchmark analyst Matthew Harrigan initiates coverage on Lionsgate Studios (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LION#NYSE">LION</a>) with a Buy rating and announces Price Target of $8.5.

LION

Benchmark Initiates Coverage On Lionsgate Studios with Buy Rating, Announces Price Target of $8.5

Trial Investigates Use of Auryon Atherectomy System in Cases with Challenging Below-the-Knee Blockages
AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced enrollment of the first patient in the Randomized Study of the Auryon Atherectomy System Used in Combination with Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone Treating Infrapopliteal Lesions in Subjects with Critical Limb Ischemia Below-the-Knee (AMBITION BTK).
AMBITION BTK is a prospective, multicenter, randomized controlled trial (RCT) designed to investigate the clinical safety and effectiveness of the Auryon Atherectomy System combined with standard balloon angioplasty, compared to balloon angioplasty alone, in treating infrapopliteal lesions in patients with Critical Limb Ischemia (CLI). The primary endpoint will be evaluated using a win-ratio approach, comparing the two treatment groups based on the following components in a hierarchical manner at 12 months: freedom from major amputation, freedom from clinically driven target lesion revascularization (CD-TLR), and primary patency.
The RCT will include up to 224 patients at up to 30 sites. In parallel, a companion registry will enroll up to 1,500 additional patients who are ineligible for the RCT and are treated with the Auryon System above or below the knee.

ANGO

AngioDynamics Enrolls First Patient In Randomized Study Of AMBITION Below-the-Knee

ORIS

Oriental Rise Holding Signs Non-Binding Letter Of Intent to Acquire 100% Equity Interests Of Fujian Daohe Tea Technology And Ningde Minji

VisionWave Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VWAV#NASDAQ">VWAV</a>) ("VisionWave" or the "Company"), a next-generation defense technology company, today announced that it has entered into a transformative funding agreement with a prominent institutional investor, securing an equity line for up to $50 million in capital through a Standby Equity Purchase Agreement (SEPA), along with a $5 million tranche funding commitment in the form of convertible notes.
This financing empowers VisionWave to execute on the strategic initiatives outlined in its investor presentation including the scaled deployment of its AI-powered multi-domain defense solutions across autonomous aerial, ground, and maritime systems.
Under the terms of the agreement, VisionWave has the right to sell up to $50 million in common stock over a 24-month period at its discretion, providing flexible, growth-focused capital. The investor also committed to funding $5 million through convertible notes to support immediate scaling efforts, of which, the first $3 million was funded upon entering into the funding agreement.
Importantly, the $5 million tranche funding includes protective covenants which prohibit the use of proceeds to pay any pre-existing liabilities accrued before the Company's business combination. This ensures that all capital raised is strictly designated for working capital and growth initiatives, reinforcing VisionWave's forward-focused strategy.

Financing

VWAV

VisionWave Secures Up To $55M In Growth Capital To Scale AI Defense Solutions, Including $50M Equity Line And $5M In Convertible Notes

General

BMRC

Bank Of Marin Bancorp Has Authorized Repurchase Of Up To $25M OF Its Common Stock Through July 31, 2027

JP Morgan analyst Matthew Boss maintains Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) with a Overweight and raises the price target from $355 to $406.

JP Morgan Maintains Overweight on Ralph Lauren, Raises Price Target to $406

Beyond, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) (the "Company"), owner of Bed Bath &amp; Beyond, Overstock, buybuy BABY, and a blockchain asset portfolio, today announced that it has sent a follow-up letter to tZERO's management and Board of Directors urging it, as tZERO's largest equity holder, to take specific and prioritized actions to unlock value and capitalize on the present favorable market conditions.
A Follow-Up Letter to tZERO Board of Directors:
Dear Members of the Board of Directors,
Further to the letter I sent last week, I want to double down on what I said, tZERO has all the foundational ingredients to lead the digital assets space in the U.S. The licenses, IP, and early market position are there. But now it's about execution.
We believe the company is at a pivotal point. To unlock the full value and capitalize on the growing institutional and regulatory momentum, we need to move quickly and deliberately. As the largest equity holder of tZERO, here are the actions we strongly recommend and would like to see prioritized:
<ul>
<li>File a shelf registration or consider leveraging Beyond as a public platform using its existing infrastructure. Either path can provide the flexibility needed for capital raises, M&amp;A activity, and broader strategic execution. The goal is to create optionality and remove constraints to growth.</li>
<li>Restructure the board by bringing in individuals with real operating and regulatory experience in digital assets. The current opportunity requires sharper, more specialized governance.</li>
<li>Find global partners who can actively drive deal flow and contribute real-world assets to the platform and give them clear incentives to help grow it. That incentive needs to go beyond just unlocking the value of their own assets. It should include true upside: where their activity helps grow the ecosystem, they participate in the value creation of the platform itself.</li>
<li>Advance the Layer 2 strategy, but only with partners who are ready to execute now. This must be tied directly to onboarding meaningful RWA volume and building usage from day one.</li>
<li>Launch a full-scale marketing and PR initiative that elevates tZERO's public presence and clearly communicates the differentiated value of our technology stack, including the Proof platform and the MAP (Marketplace Asset Protocol) infrastructure. These are meaningful assets, and we need the market to know it.</li>
<li>Convert TZROP into equity. As the largest TZROP holder, we see far more long-term value in exchanging our revenue rights for equity in the company. We believe that a conversion at fair value would simplify the cap structure, align incentives across stakeholders, and give the company significantly more flexibility to raise capital, pursue partnerships, and execute on its roadmap. This is a critical step toward creating clarity and momentum.</li>
</ul>
Some of this may already be under discussion, and that's good. But we're urging you to take clear, visible action now. There's a moment here, and we don't want to look back and say we missed it.
We're fully behind you, and we're here to help. Let's get moving.
Best, /s/ Marcus
Marcus Lemonis Executive Chairman, Beyond, Inc.

Management

BYON

Beyond Urges tZERO To Accelerate Growth Strategy, Calls For Board Restructure, Capital Flexibility, And Equity Conversion To Unlock Value

Several Esteemed Cancer Centers to Commence Patient Enrollment Before the End of September
The Registry Study, Known as PanTheR, will Expand the Safety and Performance Data of the FDA-Cleared RenovoCath&#xAE; Device, and its Associated Survival Outcomes in Patients Diagnosed with Solid Tumors
Cancer Centers in the Registry Study will Purchase RenovoCath Devices from RenovoRx
RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/RNXT#NASDAQ">RNXT</a>), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a patented, FDA-cleared drug-delivery device, today announced the launch of the PanTheR Post-Marketing Registry Study (NCT06805461).
The initiation of this study demonstrates RenovoRx's commitment to innovation and RenovoCath's current and future potential. The study will serve as a critical tool for understanding RenovoCath's safety and effectiveness in a real-world setting, providing valuable insights into long-term effectiveness and patient outcomes. Patient enrollment is expected to commence before the end of September 2025. Each cancer center participating in the registry study will purchase RenovoCath devices for use in the study from RenovoRx.
A registry study, or post-approval study, is a clinical study that involves collecting data on the long-term use and performance of a medical device, such as RenovoCath, after it has been cleared for market by the FDA. PanTheR is a multi-center, post-marketing observational registry study designed to evaluate the long-term safety of and survival outcomes for patients diagnosed with solid tumors who are treated using RenovoCath for targeted drug delivery. PanTheR will capture real-world data on the utilization of RenovoCath and generate additional safety information across a broader range of solid tumors. This data may be used to inform future clinical trial designs.
The first of multiple clinical sites to initiate patient enrollment in the PanTheR study is the University of Vermont (UVM) Cancer Center, with Dr. Conor O'Neill, Assistant Professor at the UVM Larner College of Medicine and surgical oncologist at the UVM Medical Center, serving as Principal Investigator. Additional clinical sites in the post-marketing registry study are expected to initiate enrollment soon.

RNXT

RenovoRx Launches PanTheR Post-Marketing Registry Study, To Expand Safety And Performance Data Of FDA-Cleared RenovoCath Device, And Associated Survival Outcomes In Patients Diagnosed With Solid Tumors

Jim Cramer has predicted that Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) will soar to $200, following its recent surge past $150.
Check out the <a href="https://www.benzinga.com/quote/PLTR">PLTR stock price here</a>.
What Happened: In a post on X, CNBC&#8217;s &#8216;Mad Money&#8217; host Cramer described the stock's upward movement as "like a knife through butter," signaling a bullish outlook on the AI-driven data analytics firm.
Palantir, known for its Gotham and Foundry platforms used by U.S. defense and commercial sectors, hit a fresh record high of $160.39 per share intraday on Friday.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Palantir being pushed up nicely. Right through $150 like a knife through butter. Next stop: $200. Obviously Robinhood roaring, too
&mdash; Jim Cramer (@jimcramer) <a href="https://twitter.com/jimcramer/status/1949764867268784395?ref_src=twsrc%5Etfw">July 28, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Last week, the U.S. Army awarded a $100 million contract to the Anduril-Palantir team for the delivery of a Next-Generation Command and Control (NGC2) platform prototype.
With this deal, Palantir is poised to secure an estimated $30 million from an 11-month contract, a high-priority U.S. Army project, <a href="https://www.insidermonkey.com/blog/palantir-pltr-wins-key-u-s-army-ai-contract-in-push-for-defense-growth-1573150/">reported</a> Insider Monkey, citing William Blair analyst Louie DiPalma. 
This initiative also offers the potential to boost Palantir&#8217;s annual recurring revenue by over $150 million within three years.
Wedbush analyst Dan Ives also highlighted Palantir as a key beneficiary of President Donald Trump&#8216;s &#8220;<a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46580004/trumps-ai-action-plan-to-unleash-4th-industrial-revolution-dan-ives-picks-6-stock-winners">AI Action Plan</a>,&#8221; which aims to secure U.S. leadership in the sector, and he also listed it as one of his <a href="https://www.benzinga.com/markets/equities/25/07/46463595/dan-ives-picks-5-stocks-for-2nd-half-of-2025-nvidia-palantir-microsoft-and-more-golden-age-of-tech-is-here-with-ai-revolution">top five picks</a> for the second half of 2025. 
See Also: <a href="https://www.benzinga.com/markets/equities/25/07/46655759/these-3-dividend-yielding-stocks-could-outperform-as-high-fed-rates-spark-4-9-billion-inflows-ex">These 3 Dividend-Yielding Stocks Could Outperform As High Fed Rates Spark $4.9 Billion Inflows: Expert</a>
Why It Matters: Additionally, last week on Friday, Piper Sandler analyst Brent Bracelin announced a <a href="https://www.benzinga.com/trading-ideas/movers/25/07/46635102/palantir-technologies-stock-hits-a-new-all-time-high-whats-driving-the-action">$170 price target</a> for Palantir. 
This followed Ives&#8217; target price <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46339022/palantir-could-be-the-next-big-ai-winner-says-dan-ives-sees-12-pltr-stock-surge">increase to $160 apiece</a>, underlining the growing confidence in Palantir&#8217;s artificial intelligence strategy. He described PLTR to be on a &#8220;golden path to become an AI stalwart&#8221; over the next 12 months. 
The enthusiasm of various analysts underscores their belief in the company&#8217;s potential to dominate the AI landscape, despite its forward P/E ratio of 277.778, raising valuation concerns among some investors.
While bullish analysts like Ives and Bracelin are raising their targets, the broader analyst consensus of 25 experts, as <a href="https://www.benzinga.com/quote/PLTR/analyst-ratings">tracked by Benzinga</a>, remains a &#8216;Sell&#8217; with an average price target near $80.6. Despite this, investor sentiment, propelled by key government contracts and strategic enterprise partnerships, continues to drive the stock to new heights.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/PLTR/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="387" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28071416/PLTR-ANR-new-fresh-latest-1024x387.png" alt="" class="wp-image-1003078" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28071416/PLTR-ANR-new-fresh-latest-1024x387.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28071416/PLTR-ANR-new-fresh-latest-300x113.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28071416/PLTR-ANR-new-fresh-latest-768x290.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28071416/PLTR-ANR-new-fresh-latest.png 1098w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Price Action: Palantir was up 1.41% in premarket on Monday. It has risen by 111.20% on a year-to-date basis and 486.41% over the past year.
Benzinga's Edge Stock Rankings indicate that PLTR maintains solid momentum across short, medium, and long-term periods. However, while the stock scores well on growth rankings, its value rating remains relatively weak. Additional performance details are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-3/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-3/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="155" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28071351/edge-new-PLTR-1024x155.png" alt="" class="wp-image-1003076" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28071351/edge-new-PLTR-1024x155.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28071351/edge-new-PLTR-300x46.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28071351/edge-new-PLTR-768x116.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/28071351/edge-new-PLTR.png 1167w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were higher in premarket on Monday. The SPY was up 0.18% at $638.23, while the QQQ advanced 0.37% to $568.47, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/07/46653560/bitcoin-ethereum-ripple-have-big-money-moment-as-expert-sees-incremental-institutional-buyers-driving-current-rally" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, Ripple Have ‘Big Money' Moment As Expert Sees ‘Incremental Institutional Buyers' Driving Current Rally</a></li>
</ul>
Image via Shutterstock

PLTR

Palantir's Next Stop Is $200, Says Jim Cramer As PLTR Glides 'Like A Knife Through Butter'

LOBO

LOBO EV Technologies And Strattners Explore Strategic Investment Partnership

- IsoBio,&nbsp;Inc. (IsoBio) is a U.S.-based radiotherapeutic development company focused on developing a broad pipeline of mAb-based radioisotope therapeutics, known as antibody-isotope conjugates (AICsTM), targeting both derisked and novel tumor antigens for patients in need of new cancer therapies. &nbsp;
- IsoBio has closed its initial Series Seed financing round, raising $5 million from ASP&nbsp;Isotopes&nbsp;Inc. (ASPI).
- The strategic collaboration contemplates future manufacturing opportunities for PET&nbsp;Labs (ASPI's nuclear medicine subsidiary).
- IsoBio plans to leverage the technology and global manufacturing capabilities developed by ASPI to reduce the uncertainty of isotope supply chain/manufacturing, and develop novel isotopes for radiotherapeutics.
- IsoBio was co-founded and is led by Bruce Turner, M.D., Ph.D., CEO and President, and will establish its offices in Seattle, WA and Gladwyne, PA.
- IsoBio management team to host investor call for ASPI investors on Wednesday July 30th at 10am EST. See below for dial in details.
WASHINGTON and SEATTLE and GLADWYNE, Pa., July 28, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that it has completed an initial Series Seed financing round of IsoBio, a U.S.-based radiotherapeutic development company. IsoBio plans to use the capital raised to develop potent targeted therapies for cancer patients using monoclonal antibodies against derisked and validated tumor antigens, as well as novel tumor targets, that will be combined with highly active novel isotopes to produce much-needed new treatments.
For the successful development and commercial supply of radiotherapeutics, the supply chain is critical and in recent years there have been many examples where the clinical development and commercial progress of radiotherapies have been constrained by limited supply of the required commonly used isotopes. The strategic partnership between IsoBio with ASP Isotopes Inc(including its nuclear medicine subsidiary, PET Labs) should reduce the uncertainty of the isotope supply chain and provide IsoBio with a significant advantage over other biotechnology companies trying to develop novel targeted radiotherapies particularly as some of the complex isotopes become tailored for the treatment of specific tumors and are not available for development.
IsoBio is developing radiotherapeutics containing Lutetium-177, Actinium-225, Terbium-161, and other undisclosed novel radioisotopes, which will be attached to antibodies using novel proprietary linker and conjugation technology to create highly potent antibody-isotope conjugates (AICsTM). AICs will provide a highly targeted approach for difficult to treat tumors allowing for maximal efficacy while minimizing off-target toxicity.

ASPI

IsoBio Closes $5M Seed Round Led By ASP Isotopes To Advance Antibody-Isotope Cancer Therapies; Strategic Deal Targets Radiotherapeutic Supply Chain And Manufacturing

Bank of Marin Q2 2025 Adj. EPS $0.29 Misses $0.34 Estimate, Sales $25.912M Miss $27.265M Estimate

JP Morgan analyst Matthew Boss maintains Dillard's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDS#NYSE">DDS</a>) with a Underweight and raises the price target from $368 to $458.

JP Morgan Maintains Underweight on Dillard's, Raises Price Target to $458

FRGT

Freight Technologies Secures Two-Year SaaS Contract With Salzillo To License Fleet Rocket TMS

Cantor Fitzgerald analyst Sarah James downgrades Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Overweight to Neutral and lowers the price target from $65 to $38.

Downgrades

Cantor Fitzgerald Downgrades Centene to Neutral, Lowers Price Target to $38

FBLG

FibroBiologics Files Patent Application With USPTO Covering Methods Of Generating Multipotent Cells From Fibroblasts Found In Donor Tissue For Clinical Applications

FLYE

Fly-E Group Regains Nasdaq Compliance

Press Releases

AdvisorShares Launches HVAC and Industrials ETF (Ticker: HVAC), Introducing a New Opportunity for Growth in Thematic Investing

EATZ

HVAC

Comments

AdvisorShares Hotel ETF

Noticias

Últimas noticias sobre AdvisorShares Hotel ETF (ARCA:BEDZ)

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL